Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

PARP inhibitors arrive in China via new priority review pathway

pharmaceutical-technologySeptember 04, 2018

Tag: PARP inhibitors , AstraZeneca , china

PharmaSources Customer Service